GWC members increase their investment in Micrima via a £3.8m Future Fund capital raise
GWC is pleased to announce that its members have significantly increased their investment in Micrima via a £3.8m Future Fund matched convertible loan. They were joined by Technology Venture Partners, Angel Co Fund and Intuitive Investments Group plc.
Micrima is a commercial stage company which has developed a new imaging method, the MARIA® system, which uses radio waves and not ionising X-rays to detect breast cancer. This enables more frequent scanning and higher levels of sensitivity in dense breasts, which also opens up the possibility for use on younger women. Micrima has reached a significant development milestone with initial sales of its novel breast imaging technology. Micrima is now set to finalise its latest release of its MARIA® product before embarking on a full commercial launch with distribution already established in Germany, Austria and Switzerland through an agreement with Hologic, Inc. More information on Micrima can be found at https://micrima.com/.
Adrian Waller the new CEO said “This latest round of funding allows us to take the new system and work on automatically classifying findings using the rich data set that it produces, which has every opportunity to transform the landscape of breast cancer detection. We have been very impressed by the assistance GWC has given us by introducing investors and others in the industry who can assist with the adoption of this new technology in the healthcare system”
Ian Leigh, founder of GWC commented “We are very pleased to be investors in Micima, this is a great example of an impact company – significant commercial upside combined with improving health outcomes by reducing the death rate from breast cancer ”
GWC is a network of UHNWIs and Family Offices that invest in early stage UK companies that have disruptive technology. For further information see http://www.gwcinvestor.com